Table 2.
Change in outcomes between start of treatment and three months
| Outcomes | Treatment course: MTX | Treatment course: PBO | P value |
|---|---|---|---|
| (N = 25) | (N = 21) | ||
| DAS44 | −0.08 [−0.6, 0.1] | −0.13 [−0.6, 0.1] | 0.44 |
| Number of tender joints [0 – 44] | 0 [−1.0, 1.3] | −1 [−3.5, 0.5] | 0.17 |
| Number of swollen joints [0 – 44] | −1 [−3.5, 0] | 0 [−1.5, 2.0] | 0.56 |
| CRP level | 0.2 [−0.8, 1.9] | −0.3 [−1.6, 1.6] | 0.33 |
| Number of analgesic pills/week, median | 0 [−7, 4] | 0 [−2.0, 1.5] | 0.36 |
| Number of flares/3 months | 0 [−1, 0] | 0 [−1, 0] | 0.10 |
| VAS Pain | −1 [−2.8, 0] | 0 [−2, 1] | 0.43 |
All results are displayed in medians [interquartile ranges]. MTX, methotrexate; PBO, placebo; DAS44, disease activity score based on 44 joints; CRP, C-reactive protein; VAS Pain, visual analog scale for pain.